Pfizer/Warner-Lambert
This article was originally published in The Tan Sheet
Executive Summary
FTC approves planned merger but requires divestiture of an overlapping consumer product marketed only in the U.S., Pfizer announces May 25. While neither company would say which product must be divested, Pfizer calls the requirement "baffling." The merged firm most likely will have to "rid" itself of either the Rid or Nix pediculicides, which had a combined 58.1% dollar share in the lice category for the 52 weeks ended Dec. 26, according to data from Chicago-based Information Resources, Inc. Both companies also market mouthwashes, W-L with Listerine and Pfizer with Plax. The closing is targeted for early to mid-June, Pfizer says
You may also be interested in...
Pfizer Looks To Give J&J/Merck Heartburn With Zantac 150 Switch
Pfizer Consumer Healthcare's Rx-to-OTC switch of Zantac 150 appears to be a belated attempt to counter Johnson & Johnson/Merck's approval of Maximum Strength Pepcid AC last year
Pfizer Looks To Give J&J/Merck Heartburn With Zantac 150 Switch
Pfizer Consumer Healthcare's Rx-to-OTC switch of Zantac 150 appears to be a belated attempt to counter Johnson & Johnson/Merck's approval of Maximum Strength Pepcid AC last year
Bayer Rid Pediculicide Marketing Begins With Mousse Launch
Bayer Consumer Care's inaugural marketing efforts for the newly acquired Rid brand will focus on Maximum Strength Rid Mousse aerosolized foam lice treatment, which began shipping June 22.